Pyxis Oncology (NASDAQ:PYXS) Announces Earnings Results, Beats Expectations By $0.03 EPS

Pyxis Oncology (NASDAQ:PYXS) issued its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.

Pyxis Oncology Trading Up 3.1%

PYXS opened at $1.66 on Friday. The company has a market capitalization of $138.46 million, a price-to-earnings ratio of -1.28 and a beta of 1.41. Pyxis Oncology has a 12-month low of $1.03 and a 12-month high of $5.55. The business’s fifty day simple moving average is $2.51 and its 200-day simple moving average is $2.16.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on PYXS shares. Wedbush lowered their target price on shares of Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating for the company in a report on Friday. Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a report on Thursday. Wall Street Zen raised shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a research report on Saturday. Wells Fargo & Company raised their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $8.71.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.